Holen Sie sich die Stockscreener-App
0.8599
2.38%
0.02
Handel nachbörslich:
.86
0.000100
+0.01%
Schlusskurs vom Vortag:
$0.8399
Offen:
$0.83005
24-Stunden-Volumen:
77,854
Relative Volume:
0.35
Marktkapitalisierung:
$79.95M
Einnahmen:
$5.61M
Nettoeinkommen (Verlust:
$-42.51M
KGV:
-1.8453
EPS:
-0.466
Netto-Cashflow:
$-16.86M
1W Leistung:
+3.83%
1M Leistung:
-1.96%
6M Leistung:
-31.75%
1J Leistung:
-5.51%
1-Tages-Spanne:
$0.80
$0.8792
1-Wochen-Bereich:
$0.77
$0.8792
52-Wochen-Spanne:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.8599 | 78.09M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Australia
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
CTOR Technical Analysis | Trend, Signals & Chart Patterns | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
Citius Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Armistice Capital (CTOR) files 9.99% ownership disclosure - Stock Titan
TradingKey - TradingKey
Citius Oncology, Inc. (CTOR) Eps Diluted (TTM) - Zacks Investment Research
Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks
Citius Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan
What Citius Oncol (CTOR) is doing to protect its market share (On the Radar) 2026-05-08Revenue Growth Stocks - newser.com
Financing package boosts Lymphir commercial push - The Pharma Letter
Citius Pharmaceuticals subsidiary raises up to 36.5 million dollars for LYMPHIR commercialization - Traders Union
Citius Oncology Secures New Financing to Support LYMPHIR - TipRanks
Citius Oncology Secures $36.5 Million Financing to Accelerate LYMPHIR® Commercialization and Growth - Minichart
Citius raises $36.5m for Lymphir commercialisation - Yahoo Finance
Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization - TradingView
Press Release: Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR(R) Commercialization - Moomoo
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Quantisnow
Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch - Stock Titan
Citius Oncology, Inc. announced that it expects to receive $36.5 million in funding - marketscreener.com
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms - TipRanks
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st
Citius Expands LYMPHIR Access with First European Shipment - TipRanks
Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks
Citius Oncology ships first international order of LYMPHIR to Europe - TradingView
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology Ships First International Order of LYMPHIR™ to E - GuruFocus
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - ChartMill
Citius Oncology, Inc. Receives Nasdaq Compliance Notice for CTOR Common Stock – Form 8-K April 2026 Filing - Minichart
Citius Oncology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Citius Oncology (NASDAQ: CTOR) on sub-$1 bid price and delisting risk - Stock Titan
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):